Skye Bioscience, Inc.
SKYE
$3.29
-$0.26-7.32%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -9.72% | 8.48% | 15.16% | -96.18% | 310.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 117.04% | 91.14% | 161.02% | 42.37% | 195.66% |
| Operating Income | -117.04% | -91.14% | -161.02% | -42.37% | -195.66% |
| Income Before Tax | -123.21% | -121.25% | -120.51% | 84.37% | -154.02% |
| Income Tax Expenses | -58.02% | 0.00% | -- | -- | 125.00% |
| Earnings from Continuing Operations | -123.02% | -121.20% | -120.51% | 84.37% | -153.99% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -123.02% | -121.20% | -120.51% | 84.37% | -153.99% |
| EBIT | -117.04% | -91.14% | -161.02% | -42.37% | -195.66% |
| EBITDA | -115.58% | -89.11% | -158.53% | -41.65% | -198.17% |
| EPS Basic | -117.42% | -56.16% | 31.57% | 96.83% | 74.47% |
| Normalized Basic EPS | -118.73% | -27.18% | 35.26% | 76.55% | 73.73% |
| EPS Diluted | -117.42% | -55.56% | 31.57% | 96.83% | 74.47% |
| Normalized Diluted EPS | -118.73% | -27.18% | 35.26% | 76.55% | 73.73% |
| Average Basic Shares Outstanding | 2.56% | 41.61% | 222.28% | 392.60% | 895.04% |
| Average Diluted Shares Outstanding | 2.56% | 41.61% | 222.28% | 392.60% | 895.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |